Educated Patient® Lung Cancer Summit: March 6, 2021

Treating patients with lung cancer always calls for a focus on informed and shared decision-making, according to expert oncologists.

February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.

The U.S. FDA has approved treatment with Ibtrozi for patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer.

Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews

FDA granted priority review to Zepzelca plus Tecentriq for first-line maintenance in extensive-stage small cell lung cancer.

Amanda Snyder, a cancer survivor, became an oncology nurse to provide support she once lacked, now leading innovative therapies for patients.